MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 8
- Registration Number
- NCT03811652
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 84
- Registration Number
- NCT03794544
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2020-06-05
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 20
- Registration Number
- NCT03745937
- Locations
- 🇩🇪
Research Site, Neuss, Germany
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 88
- Registration Number
- NCT03654313
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 51
- Registration Number
- NCT03625778
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 213
- Registration Number
- NCT03611556
- Locations
- 🇪🇸
Research Site, Pamplona, Spain
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 28
- Registration Number
- NCT03596177
- Locations
- 🇬🇧
Research Site, Cambridge, United Kingdom
A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 593
- Registration Number
- NCT03578809
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
D2560C00015 FluMist Annual Safety Study 2018
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 300
- Registration Number
- NCT03564444
- Locations
- 🇺🇸
Research Site, Portland, Oregon, United States
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 51
- Registration Number
- NCT03555994
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath